📊 ATRA Key Takeaways
Investment Thesis
Atara Biotherapeutics exhibits severe financial distress with negative stockholders' equity of -$38.5M despite profitable income statement metrics, indicating balance sheet insolvency. The company burns $50.9M in operating cash flow annually while generating only $120.8M in revenue, creating an unsustainable cash burn rate that threatens operational continuity without external financing.
ATRA Strengths
- High operating margin of 29.7% and net margin of 27.1% demonstrate operational profitability on reported earnings
- Positive net income of $32.7M and operating income of $35.9M show business can generate earnings
- Interest coverage ratio of 9.5x indicates ability to service debt obligations from operations
ATRA Risks
- Negative stockholders' equity of -$38.5M signals balance sheet insolvency and technical bankruptcy status
- Operating cash flow of -$50.9M vastly exceeds net income, indicating earnings quality issues and cash burn fundamentally unsustainable
- Current ratio of 0.82x and quick ratio of 0.82x show insufficient liquid assets to cover short-term liabilities; immediate liquidity crisis risk
- Total liabilities of $58.7M exceed total assets of $20.2M by nearly 3x, representing structural financial distress
- FCF margin of -42.2% demonstrates business model cannot sustain operations without external capital raises
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Stockholders' equity recovery and balance sheet recapitalization
- Cash burn rate and months of liquidity remaining
- Revenue growth sustainability and operating leverage improvement
ATRA Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ATRA Profitability Ratios
ATRA vs Healthcare Sector
How Atara Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ATRA Balance Sheet & Liquidity
ATRA 5-Year Financial Trend
5-Year Trend Summary: Atara Biotherapeutics, Inc.'s revenue has grown significantly by 103% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.41 indicates the company is currently unprofitable.
ATRA Growth Metrics (YoY)
ATRA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.1M | -$19.0M | $-2.93 |
| Q2 2024 | $957.0K | -$19.0M | $-3.10 |
| Q1 2024 | $1.2M | -$31.8M | $-0.23 |
| Q3 2023 | $2.1M | $18.5M | $-0.66 |
| Q2 2023 | $957.0K | $18.5M | $0.18 |
| Q1 2023 | $1.2M | -$74.8M | $-0.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATRA Capital Allocation
ATRA SEC Filings
Access official SEC EDGAR filings for Atara Biotherapeutics, Inc. (CIK: 0001604464)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATRA
What is the AI rating for ATRA?
Atara Biotherapeutics, Inc. (ATRA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATRA's key strengths?
High operating margin of 29.7% and net margin of 27.1% demonstrate operational profitability on reported earnings. Positive net income of $32.7M and operating income of $35.9M show business can generate earnings.
What are the risks of investing in ATRA?
Negative stockholders' equity of -$38.5M signals balance sheet insolvency and technical bankruptcy status. Operating cash flow of -$50.9M vastly exceeds net income, indicating earnings quality issues and cash burn fundamentally unsustainable.
What is ATRA's revenue and growth?
Atara Biotherapeutics, Inc. reported revenue of $120.8M.
Does ATRA pay dividends?
Atara Biotherapeutics, Inc. does not currently pay dividends.
Where can I find ATRA SEC filings?
Official SEC filings for Atara Biotherapeutics, Inc. (CIK: 0001604464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATRA's EPS?
Atara Biotherapeutics, Inc. has a diluted EPS of $2.57.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.